David S. Hong, MD, discusses which disease subgroups may benefit from treatment with larotrectinib.
David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses which disease subgroups may benefit from treatment with larotrectinib (Vitrakvi).
Previously in 2018, the FDA granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. The other FDA approved TRK inhibitor is entrectinib (Rozlytrek).
Results from multiple studies, including the phase 2 NAVIGATE (NCT02576431), phase 1 LOXO-TRK-14001 trial (NCT02122913), and phase 1/2 SCOUT trial (NCT02637687), sought to evaluate larotrectinib as an NTRK inhibitor and have confirmed the long-term response and efficacy of larotrectinib in patients with lung cancer who harbor NTRK fusions.
Here, Hong notes that patients who have either primary central nervous system (CNS) or brain are benefiting from larotrectinib, and highlights other subgroups that may as well.
Transcription:
0:10 | The CNS is a component of it. We didn't present the data at ASCO [last] year, but there are clearly patients who have either primary CNS, or who also have brain metastases who are benefiting from larotrectinib. A highlight of entrectinib is that it seems to be brain penetrating, but we know that both molecules can penetrate the brain.
0:40 | Some of these patients, particularly the pediatric patients with infantile fibrosarcoma, who got the drug had significant tumor shrinkage and they were able to go in and resect the tumor out in a way, NGS [next generation sequencing] like in a neoadjuvant setting. Primarily, as more patients are becoming or getting NGS earlier in the staging, I think we will identify these patients that may benefit from these drugs earlier, as soon as they're identified within transfusion.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More